Testing etavopivat for sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 12 years or older
- Have a confirmed diagnosis of sickle cell disease (like HbSS or HbSβ0-thalassemia)
- Have had 1 to 15 sickle cell pain crises in the past year (documented by your doctor)
- Have a hemoglobin level between 5.0 and 10.0 g/dL at screening
- Not be on regular blood transfusions or have had more than 5 transfusions in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
This trial tests a new medicine called ITU512 in two groups: healthy volunteers and people with sickle cell disease. In the second part, researchers want to see if ITU512 can help manage sickle cell disease.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
This trial tests a new drug, etavopivat, to see how it works in children with sickle cell disease. It may help reduce painful crises and other complications.
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.